0000000000007080

AUTHOR

M. Fulco

showing 4 related works from this author

Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2

1997

Like other members of the tumor necrosis factor (TNF) receptor family, p55 TNF receptor 1 (TNF-R1) lacks intrinsic signaling capacity and transduces signals by recruiting associating molecules. The TNF-R1 associated death domain protein interacts with the p55 TNF-R1 cytoplasmic domain and recruits the Fas-associated death domain protein (which directly activates the apoptotic proteases), the protein kinase receptor interacting protein, and TNF receptor-associated factor 2 (TRAF2). TRAF2 has previously been demonstrated to activate both transcription factor nuclear factor kappaB (NFkappaB) and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) pathway, which in turn stimu…

MAP kinase kinase kinasebiologyChemistryCyclin-dependent kinase 2Cell BiologyMitogen-activated protein kinase kinaseBiochemistryProtein kinase RMAP2K7Cancer researchbiology.proteinCyclin-dependent kinase 9ASK1c-RafMolecular BiologyJournal of Biological Chemistry
researchProduct

Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.

1998

Objectives: α-Interferons (α-IFN) have been shown to be effective in the treatment of chronic viral C hepatitis, but their efficacy remains unsatisfactory. Recently natural β-interferon (β-IFN) administered by intravenous infusion has been used successfully. Methods: To evaluate the efficacy and safety of intravenous β-IFN administration we treated 20 patients with histologically proven chronic hepatitis C who were nonresponders to at least two previous courses of α-IFN treatment. All patients received 6 million units (MU) of natural human fibroblast β-IFN by drip infusion, 6 times per wk for 8 wk and were followed up for 6 months after suspension of treatment. Results: Five patients (25%) …

AdultMalemedicine.medical_specialtyGenotypeHepacivirusHepatitis C virusmedicine.medical_treatmentAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyInternal medicinemedicineHumansInfusions IntravenousInterferon alfaHepatitisbiologyHepatologybusiness.industryGastroenterologyInterferon-alphaImmunotherapyInterferon-betaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseSurgeryTreatment OutcomeRNA ViralFemaleViral diseasebusinessViral loadmedicine.drugThe American journal of gastroenterology
researchProduct

Evaluation by Ultrasound of Abdominal Lymphadenopathy in Chronic Hepatitis C

1999

Objective: Abdominal ultrasound has shown a frequent association between abdominal lymphadenopathy (LA) and chronic liver disease, but contradictory data have been reported on its relationship with the main parameters of hepatic function. The aim of this study was to correlate the prevalence of LA in patients who were chronic hepatitis-anti-hepatitis C virus positive prospectively followed-up over the last 3 years and its relationship with biochemical and histological data. Methods: 136 RIBA II confirmed positive patients with ALT levels >2N were included. None of these had been or was at the time of study on interferon treatment. Ultrasound was performed using a Toshiba SSA 240 A apparatus…

MalePathologymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaTime FactorBiopsyHepatitis C virusmedicine.disease_causeChronic liver diseaseGastroenterologyFollow-Up StudieLiver diseaseLiver Function TestsInternal medicineBiopsyPrevalencemedicineHumansLymphatic DiseasesUltrasonographyHepatologymedicine.diagnostic_testLiver Function TestReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyCase-control studyClinical Enzyme TestHepatitis CClinical Enzyme TestsHepatitis C ChronicMiddle Agedmedicine.diseasemedicine.anatomical_structureLiverCase-Control StudiesAbdomenFemaleLymphatic DiseaseCase-Control StudieLiver function testsbusinessFollow-Up StudiesHumanAmerican Journal of Gastroenterology
researchProduct

Comparative responses to three different types of interferon-α in patients with chronic hepatitis C

1999

We investigated the efficacy and tolerability of three different types of interferon-alpha, administered with the same schedule to naive patients with chronic hepatitis C. One hundred and seven patients with histologically proven chronic hepatitis C were enrolled during a period of three years and randomly divided into three groups, to receive (a) leukocyte-interferon-alpha, 6 MU three times a week for 4 months, followed by 3 MU three times a week for 8 months (Group I); (b) recombinant-IFN-alpha-2a, with the same schedule (Group II); and (c) lymphoblastoid-IFN-alpha-N1, with the same schedule (Group III). All patients were followed-up for 6 months to evaluate the long-term response. The 'C…

Malemedicine.medical_specialtyTime FactorsCirrhosisAlpha interferonGastroenterologyStatistics Nonparametriclaw.inventionRandomized controlled triallawInternal medicinemedicineHumansAdverse effectAgedAnalysis of Variancebusiness.industryBiopsy NeedleRemission InductionInterferon-alphaGamma globulinGeneral MedicineHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsLiverTolerabilityInterferon Type IImmunologyFemaleAnalysis of variancebusiness
researchProduct